AXGNHIGH SIGNALFINANCIAL10-K

AXGN shows severe operational deterioration with operating losses more than doubling to $7.8M while operating cash flow collapsed 82% to just $812K, despite maintaining strong balance sheet liquidity.

The dramatic widening of operating losses combined with the near-collapse of operating cash flow suggests the company is burning through cash at an unsustainable rate despite revenue operations. While the balance sheet remains healthy with increased cash and equity positions, the operational metrics indicate serious underlying business challenges that could threaten long-term viability if not addressed.

Comparing 2026-02-24 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

AXGN's financial profile shows a stark disconnect between balance sheet strength and operational performance. While cash, inventory, and stockholders' equity all grew 24-29% and current liabilities decreased 23%, core operational metrics deteriorated severely with operating losses doubling, net losses increasing 58%, and operating cash flow plummeting 82%. This combination suggests the company may be funding deteriorating operations through equity raises or debt, creating a potentially unsustainable trajectory despite the currently strong liquidity position.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+354.3%
$624K$2.8M

Interest expense surged 354.3% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-138.8%
-$3.3M-$7.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-82.1%
$4.5M$812K

Operating cash flow fell 82.1% — earnings quality concerns; investigate working capital changes and non-cash items.

Net Income
P&L
-57.6%
-$10.0M-$15.7M

Net income declined 57.6% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+29%
$27.6M$35.5M

Cash grew 29% — improving liquidity position supports investment and shareholder returns.

Inventory
Balance Sheet
+27.7%
$33.2M$42.4M

Inventory built 27.7% — monitor whether demand supports this build or if write-downs may follow.

Stockholders Equity
Balance Sheet
+24%
$103.9M$128.8M

Equity base grew 24% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
-23%
$30.6M$23.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
+21.4%
$99.2M$120.4M

Current assets grew 21.4% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+20.8%
$3.1M$3.7M

Capex increased 20.8% — ongoing investment in capacity or infrastructure for future growth.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-26
ADDED
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 99 Item 9A.
FORWARD-LOOKING STATEMENTS From time to time, in reports filed with the U.S.
MARKET, INDUSTRY AND OTHER DATA This Annual Report on Form 10-K contains estimates, projections, and other information concerning our industry, and our business, including data regarding the estimated size of those markets.
Information that is based on estimates, forecasts, projections, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general publications, government data, and similar sources.
+7 more — sign up free →
REMOVED
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosure 100 Item 9A.
Form 10-K Summary 112 Signatures 113 P3 Table of Conten t FORWARD-LOOKING STATEMENTS From time to time, in reports filed with the U.S.
Our platform for peripheral nerve repair features a comprehensive portfolio of products, including: Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site.
Axoguard Nerve Connector , a porcine (pig) submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed peripheral nerves.
Axoguard Nerve Protector , a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while minimizing soft tissue attachments.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →